Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Cash from Operations (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Cash from Operations for 11 consecutive years, with 69285000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 18.67% to 69285000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 394736000.0 through Dec 2025, down 13.14% year-over-year, with the annual reading at 394736000.0 for FY2025, 13.14% down from the prior year.
  • Cash from Operations for Q4 2025 was 69285000.0 at Intellia Therapeutics, up from 76899000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 52376000.0 in Q1 2021, with the low at 148930000.0 in Q1 2025.
  • Average Cash from Operations over 5 years is 84800950.0, with a median of 84964000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations tumbled 192.27% in 2021, then skyrocketed 35.58% in 2024.
  • Over 5 years, Cash from Operations stood at 54651000.0 in 2021, then crashed by 64.44% to 89869000.0 in 2022, then decreased by 3.54% to 93054000.0 in 2023, then grew by 8.45% to 85195000.0 in 2024, then rose by 18.67% to 69285000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 69285000.0, 76899000.0, and 99622000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.